HRP20230168T1 - Inhibicija mutanta idh-1 - Google Patents
Inhibicija mutanta idh-1 Download PDFInfo
- Publication number
- HRP20230168T1 HRP20230168T1 HRP20230168TT HRP20230168T HRP20230168T1 HR P20230168 T1 HRP20230168 T1 HR P20230168T1 HR P20230168T T HRP20230168T T HR P20230168TT HR P20230168 T HRP20230168 T HR P20230168T HR P20230168 T1 HRP20230168 T1 HR P20230168T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- use according
- glioma
- idh
- mutation
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- 208000032612 Glial tumor Diseases 0.000 claims 5
- 206010018338 Glioma Diseases 0.000 claims 5
- 229940125904 compound 1 Drugs 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 claims 1
- 208000030173 low grade glioma Diseases 0.000 claims 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Claims (11)
1. Farmaceutski pripravak koji sadrži Spoj 1:
[image]
za upotrebu u postupku liječenja glioma koji nosi mutaciju izocitrat dehidrogenaze-1 (IDH-1) kod odraslog ljudskog pacijenta, pri čemu postupak uključuje davanje pacijentu 150 mg Spoja 1 dva puta dnevno (BID) tijekom ciklusa liječenja.
2. Farmaceutski pripravak za upotrebu prema zahtjevu 1, naznačen time što je gliom uznapredovali gliom koji se ponovno pojavio ili napredovao prije primjene Spoja 1.
3. Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 1-2, naznačen time što je, prije primjene Spoja 1, pacijentu dijagnosticiran histološki ili citološki potvrđen uznapredovali gliom s mutiranim genom IDH-1 ili multiformni glioblastom s potvrđenom bolesti s mutiranim genom IDH-1 s prvim ili drugim recidivom.
4. Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 1-3, naznačen time što je pacijentu dijagnosticiran gliom niskog stupnja ili sekundarni multiformni glioblastom (GBM).
5. Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time što je mutacija IDH-1 mutacija R132X.
6. Farmaceutski pripravak za upotrebu prema zahtjevu 5, naznačen time što je mutacija R132X odabrana od R132L, R132G i R132S.
7. Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time što se farmaceutski pripravak koji sadrži Spoj 1 daje pacijentu oralno.
8. Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time što se Spoj 1 primjenjuje kao jedno sredstvo za liječenje glioma koji nosi mutaciju IDH-1.
9. Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time što tijek liječenja traje najmanje 15 uzastopnih dana.
10. Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time što je tijek liječenja između 15 uzastopnih dana i 6 mjeseci.
11. Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 1-9, naznačen time što tijek liječenja traje najmanje 6 mjeseci.
Applications Claiming Priority (20)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862672461P | 2018-05-16 | 2018-05-16 | |
| US201862672462P | 2018-05-16 | 2018-05-16 | |
| US201862680571P | 2018-06-04 | 2018-06-04 | |
| US201862680566P | 2018-06-04 | 2018-06-04 | |
| US201862680560P | 2018-06-04 | 2018-06-04 | |
| US201862680562P | 2018-06-04 | 2018-06-04 | |
| US201862692605P | 2018-06-29 | 2018-06-29 | |
| US201862692598P | 2018-06-29 | 2018-06-29 | |
| US201862692591P | 2018-06-29 | 2018-06-29 | |
| US201862692604P | 2018-06-29 | 2018-06-29 | |
| US201862692601P | 2018-06-29 | 2018-06-29 | |
| US201862773562P | 2018-11-30 | 2018-11-30 | |
| US201962798687P | 2019-01-30 | 2019-01-30 | |
| US201962798690P | 2019-01-30 | 2019-01-30 | |
| US201962798681P | 2019-01-30 | 2019-01-30 | |
| US201962798684P | 2019-01-30 | 2019-01-30 | |
| US201962798677P | 2019-01-30 | 2019-01-30 | |
| US201962812367P | 2019-03-01 | 2019-03-01 | |
| PCT/US2019/032747 WO2019222553A1 (en) | 2018-05-16 | 2019-05-16 | Inhibiting mutant idh-1 |
| EP19728271.8A EP3720442B1 (en) | 2018-05-16 | 2019-05-16 | Inhibiting mutant idh-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230168T1 true HRP20230168T1 (hr) | 2023-05-12 |
Family
ID=85705783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230168TT HRP20230168T1 (hr) | 2018-05-16 | 2019-05-16 | Inhibicija mutanta idh-1 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4215197A1 (hr) |
| DK (1) | DK3720442T3 (hr) |
| ES (1) | ES2941079T3 (hr) |
| FI (1) | FI3720442T3 (hr) |
| HR (1) | HRP20230168T1 (hr) |
| LT (1) | LT3720442T (hr) |
| MD (1) | MD3720442T2 (hr) |
| PL (1) | PL3720442T3 (hr) |
| RS (1) | RS64069B1 (hr) |
| SI (1) | SI3720442T1 (hr) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6648115B2 (ja) | 2014-09-19 | 2020-02-14 | フォーマ セラピューティクス，インコーポレイテッド | 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジン−２（１ｈ）−オンキノリノン誘導体 |
| US9771349B2 (en) | 2014-09-19 | 2017-09-26 | Forma Therapeutics, Inc. | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| CA2961807A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| US9624175B2 (en) | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| WO2016171756A1 (en) | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
-
2019
- 2019-05-16 FI FIEP19728271.8T patent/FI3720442T3/fi active
- 2019-05-16 MD MDE20201055T patent/MD3720442T2/ro unknown
- 2019-05-16 RS RS20230221A patent/RS64069B1/sr unknown
- 2019-05-16 ES ES19728271T patent/ES2941079T3/es active Active
- 2019-05-16 SI SI201930471T patent/SI3720442T1/sl unknown
- 2019-05-16 HR HRP20230168TT patent/HRP20230168T1/hr unknown
- 2019-05-16 DK DK19728271.8T patent/DK3720442T3/da active
- 2019-05-16 EP EP22216450.1A patent/EP4215197A1/en active Pending
- 2019-05-16 LT LTEPPCT/US2019/032747T patent/LT3720442T/lt unknown
- 2019-05-16 PL PL19728271.8T patent/PL3720442T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4215197A1 (en) | 2023-07-26 |
| MD3720442T2 (ro) | 2023-09-30 |
| SI3720442T1 (sl) | 2023-06-30 |
| DK3720442T3 (da) | 2023-03-27 |
| ES2941079T3 (es) | 2023-05-16 |
| LT3720442T (lt) | 2023-04-25 |
| RS64069B1 (sr) | 2023-04-28 |
| PL3720442T3 (pl) | 2023-05-29 |
| FI3720442T3 (fi) | 2023-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018111728A5 (hr) | ||
| Ruparel et al. | Direct effect of endodontic sealers on trigeminal neuronal activity | |
| JP2017518334A5 (hr) | ||
| HRP20230809T1 (hr) | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika | |
| HRP20230935T1 (hr) | Postupci za liječenje i profilaksu hiv-a i aids-a | |
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| JP2017128610A (ja) | 併用ａｌｓ療法 | |
| JP2017517553A5 (hr) | ||
| JP2020500152A5 (hr) | ||
| MX2020012377A (es) | Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades. | |
| JP2019530706A5 (hr) | ||
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| Giaccone et al. | A placebo-controlled phase ii study of ruxolitinib in combination with pemetrexed and cisplatin for first-line treatment of patients with advanced nonsquamous non–small-cell lung cancer and systemic inflammation | |
| PH12021550218A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| RU2019121690A (ru) | Дексмедетомидин или медетомидин для применения для лечения сепарационной тревожности у собак | |
| JP2019507786A5 (hr) | ||
| JP2016505050A5 (hr) | ||
| JP2020500864A5 (hr) | ||
| RU2017127509A (ru) | Композиции и способы для улучшенного мышечного метаболизма | |
| HRP20230168T1 (hr) | Inhibicija mutanta idh-1 | |
| JPWO2019241442A5 (hr) | ||
| JP4854198B2 (ja) | 慢性リンパ性白血病の処置のためのナイトロジェンマスタードアナログとイマチニブの組み合わせ剤 | |
| HRP20171177T1 (hr) | Formulacija koja obuhvaća spoj benzotiazolona | |
| JP2019509309A5 (hr) | ||
| JP2015501849A5 (hr) |